Skip to main content
Erschienen in: Annals of Nuclear Medicine 12/2022

20.10.2022 | Original Article

Consistency and prognostic value of preoperative staging and postoperative pathological staging using 18 F-FDG PET/MRI in patients with non-small cell lung cancer

verfasst von: Akiko Kajiyama, Kimiteru Ito, Hirokazu Watanabe, Sunao Mizumura, Shun-ichi Watanabe, Yasushi Yatabe, Tatsuya Gomi, Masahiko Kusumoto

Erschienen in: Annals of Nuclear Medicine | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

In recent years, positron emission tomography/magnetic resonance imaging (PET/MRI) has been clinically used as a method to diagnose non-small cell lung cancer (NSCLC). This study aimed to evaluate the concordance of staging and prognostic ability of NSCLC patients using thin-slice computed tomography (CT) and 18F-fluorodeoxyglucose (FDG) PET/MRI.

Methods

This retrospective study was performed on consecutive NSCLC patients who underwent both diagnostic CT and 18F-FDG PET/MRI before surgery between November 2015 and May 2019. The cTNM staging yielded from PET/MRI was compared with CT and pathological staging, and concordance was investigated, defining pathological findings as reference. To assess the prognostic value of disease-free survival (DFS) and overall survival (OS), we dichotomized the typical prognostic factors and TNM classification staging (Stage I vs. Stage II or higher). Kaplan–Meier curves derived by the log-rank test were generated, and univariate and multivariate analyses were performed to identify the factors associated with DFS and OS.

Results

A total of 82 subjects were included; PET/MRI staging was more consistent (59 of 82) with pathological staging than with CT staging. There was a total of 21 cases of CT and 11 cases of PET/MRI that were judged as cStage I, but were actually pStage II or pStage III. CT tended to judge pN1 or pN2 as cN0 compared to PET/MRI. There was a significant difference between NSCLC patients with Stage I and Stage II or higher by PET/MRI staging as well as prognosis prediction of DFS by pathological staging (P < 0.001). In univariate analysis, PET/MRI, CT, and pathological staging (Stage I or lower vs. Stage II or higher) all showed significant differences as prognostic factors of recurrence or metastases. In multivariate analysis, pathological staging was the only independent factor for recurrence (P = 0.009), and preoperative PET/MRI staging was a predictor of patient survival (P = 0.013).

Conclusions

In NSCLC, pathologic staging was better at predicting recurrence, and preoperative PET/MRI staging was better at predicting survival. Preoperative staging by PET/MRI was superior to CT in diagnosing hilar and mediastinal lymph-node metastases, which contributed to the high concordance with pathologic staging.
Literatur
1.
Zurück zum Zitat Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. PubMedCrossRef Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. PubMedCrossRef
2.
Zurück zum Zitat Li F, Sher A, Kohan A, Vercher-Coonejero J, Rajiah P. PET/MRI in lung cancer. Semin Roentgenol. 2014;49(4):291–303. CrossRef Li F, Sher A, Kohan A, Vercher-Coonejero J, Rajiah P. PET/MRI in lung cancer. Semin Roentgenol. 2014;49(4):291–303. CrossRef
3.
Zurück zum Zitat Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V, et al. Comparative performance of 18F-FDG PET/MRI and 18F-FDG PET/CT in detection and characterization of pulmonary lesions in 121 oncologic patients. J Nucl Med. 2016;57(4):582–6. PubMedCrossRef Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V, et al. Comparative performance of 18F-FDG PET/MRI and 18F-FDG PET/CT in detection and characterization of pulmonary lesions in 121 oncologic patients. J Nucl Med. 2016;57(4):582–6. PubMedCrossRef
4.
Zurück zum Zitat Lakshmanaprabu SK, Mohanty SN, Shankar K, Arunkumar N, Ramirez G. Optimal deep learning model for classification of lung cancer on CT images. Future Gener Comp Sy. 2019;92:374–82. CrossRef Lakshmanaprabu SK, Mohanty SN, Shankar K, Arunkumar N, Ramirez G. Optimal deep learning model for classification of lung cancer on CT images. Future Gener Comp Sy. 2019;92:374–82. CrossRef
5.
Zurück zum Zitat Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D, et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer. 2008;61(1):35–43. PubMedCrossRef Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D, et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer. 2008;61(1):35–43. PubMedCrossRef
6.
Zurück zum Zitat Sodickson A, Baeyens PF, Andriole KP, Prevedello LM, Nawfel RD, Hnason R, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology. 2009;251(1):175–84. PubMedCrossRef Sodickson A, Baeyens PF, Andriole KP, Prevedello LM, Nawfel RD, Hnason R, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology. 2009;251(1):175–84. PubMedCrossRef
7.
Zurück zum Zitat Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248(2):632–42. PubMedCrossRef Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248(2):632–42. PubMedCrossRef
8.
Zurück zum Zitat Sommer G, Koenigkam-Santos M, Biederer J, Puderbach M. Role of MRI for detection and characterization of pulmonary nodules. Radiology. 2014;54(5):470–7. CrossRef Sommer G, Koenigkam-Santos M, Biederer J, Puderbach M. Role of MRI for detection and characterization of pulmonary nodules. Radiology. 2014;54(5):470–7. CrossRef
9.
Zurück zum Zitat Plathow C, Aschoff P, Lichy MP, Eschmann S, Heur T, Brink I, et al. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer-initial results. Invest Radiol. 2008;43(5):290–7. PubMedCrossRef Plathow C, Aschoff P, Lichy MP, Eschmann S, Heur T, Brink I, et al. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer-initial results. Invest Radiol. 2008;43(5):290–7. PubMedCrossRef
10.
Zurück zum Zitat Heusch P, Buchbender C, Kohler J, Nensa F, Gauler T, Gomez B, et al. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med. 2014;55(3):373–8. PubMedCrossRef Heusch P, Buchbender C, Kohler J, Nensa F, Gauler T, Gomez B, et al. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med. 2014;55(3):373–8. PubMedCrossRef
11.
Zurück zum Zitat Lee SM, Goo JM, Park CM, Yoon SH, Paeng JC, Cheon GJ, et al. Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT. Eur Radiol. 2016;26(11):3850–7. PubMedCrossRef Lee SM, Goo JM, Park CM, Yoon SH, Paeng JC, Cheon GJ, et al. Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT. Eur Radiol. 2016;26(11):3850–7. PubMedCrossRef
12.
Zurück zum Zitat Kirchner J, Sawicki LM, Nensa F, Schaarschmidt BM, Reis H, Ingenwerth M, et al. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019;46(2):437–45. PubMedCrossRef Kirchner J, Sawicki LM, Nensa F, Schaarschmidt BM, Reis H, Ingenwerth M, et al. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019;46(2):437–45. PubMedCrossRef
13.
Zurück zum Zitat Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, et al. Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT? Eur Radiol. 2017;27(2):681–8. PubMedCrossRef Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, et al. Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT? Eur Radiol. 2017;27(2):681–8. PubMedCrossRef
14.
Zurück zum Zitat Delso G, Martinez-Möller A, Bundschuh RA, Ladebeck R, Candidus Y, Faul D, et al. Evaluation of the attenuation properties of MR equipment for its use in a whole-body PET/MR scanner. Phys Med Biol. 2010;55(15):4361–74. PubMedCrossRef Delso G, Martinez-Möller A, Bundschuh RA, Ladebeck R, Candidus Y, Faul D, et al. Evaluation of the attenuation properties of MR equipment for its use in a whole-body PET/MR scanner. Phys Med Biol. 2010;55(15):4361–74. PubMedCrossRef
15.
Zurück zum Zitat Messerli M, Barbosa FDG, Marcon M, Muehlematter UJ, Stolzmann P, Warschkow R, et al. Value of PET/MRI for assessing tumor resectability in NSCLC-intra-individual comparison with PET/CT. Br J Radiol. 2018;92:20180379. PubMedCentralCrossRef Messerli M, Barbosa FDG, Marcon M, Muehlematter UJ, Stolzmann P, Warschkow R, et al. Value of PET/MRI for assessing tumor resectability in NSCLC-intra-individual comparison with PET/CT. Br J Radiol. 2018;92:20180379. PubMedCentralCrossRef
16.
Zurück zum Zitat Fleichsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL. PET/MRI and PET/CT in lung lesions and thoracic malignancies. Semin Nucl Med. 2015;45:268–81. CrossRef Fleichsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL. PET/MRI and PET/CT in lung lesions and thoracic malignancies. Semin Nucl Med. 2015;45:268–81. CrossRef
17.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. PubMedCrossRef Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. PubMedCrossRef
18.
Zurück zum Zitat Chansky K, Sculier JP, Crowley JJ, Giroux D, Meerbeeck JV, Goldstraw P. The international association for the study of lung cancer staging project prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801. PubMedCrossRef Chansky K, Sculier JP, Crowley JJ, Giroux D, Meerbeeck JV, Goldstraw P. The international association for the study of lung cancer staging project prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801. PubMedCrossRef
19.
Zurück zum Zitat Sculier JP, Chansky K, Crowley JJ, Meerbeeck JV, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease as expressed by the 6th edition of the TNM classification of malignant tumours and the proposals for the 7th edition. J Thorac Oncol. 2008;3(5):457–66. PubMedCrossRef Sculier JP, Chansky K, Crowley JJ, Meerbeeck JV, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease as expressed by the 6th edition of the TNM classification of malignant tumours and the proposals for the 7th edition. J Thorac Oncol. 2008;3(5):457–66. PubMedCrossRef
20.
Zurück zum Zitat Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUV max) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC lung cancer staging project. J Thorac Oncol. 2008;3(1):6–12. PubMedCrossRef Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUV max) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC lung cancer staging project. J Thorac Oncol. 2008;3(1):6–12. PubMedCrossRef
21.
Zurück zum Zitat Lim W, Ridge CA, Nicholson AG, Quant SM. The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant Imaging Med Surg. 2018;8(7):709–18. PubMedPubMedCentralCrossRef Lim W, Ridge CA, Nicholson AG, Quant SM. The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant Imaging Med Surg. 2018;8(7):709–18. PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eight edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10(7):990–1003. PubMedCrossRef Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eight edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10(7):990–1003. PubMedCrossRef
23.
Zurück zum Zitat Nomori H, Ohba Y, Yoshimoto K, Shibata H, Shiraishi K, Mori T. Positron emission tomography in lung cancer. Gen Thorac Cardiovasc Surg. 2009;57(4):184–91. PubMedCrossRef Nomori H, Ohba Y, Yoshimoto K, Shibata H, Shiraishi K, Mori T. Positron emission tomography in lung cancer. Gen Thorac Cardiovasc Surg. 2009;57(4):184–91. PubMedCrossRef
24.
Zurück zum Zitat Iwano S, Ito S, Tsuchiya K, Kato K, Naganawa S. What causes false-negative PET findings for solid-type lung cancer? Lung Cancer. 2013;79(2):132–6. PubMedCrossRef Iwano S, Ito S, Tsuchiya K, Kato K, Naganawa S. What causes false-negative PET findings for solid-type lung cancer? Lung Cancer. 2013;79(2):132–6. PubMedCrossRef
25.
Zurück zum Zitat Biederer J, Schoene A, Freitag S, Reuter M, Heller M. Simulated pulmonary nodules implanted in a dedicated porcine chest phantom: sensitivity of MR imaging for detection. Radiology. 2003;227(2):475–83. PubMedCrossRef Biederer J, Schoene A, Freitag S, Reuter M, Heller M. Simulated pulmonary nodules implanted in a dedicated porcine chest phantom: sensitivity of MR imaging for detection. Radiology. 2003;227(2):475–83. PubMedCrossRef
26.
Zurück zum Zitat Koyama H, Ohno Y, Kono A, Takenaka D, Maniwa Y, Nishimura Y, et al. Quantitative and qualitative assessment of non-contrast-enhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects. Eur Radiol. 2008;18(10):2120–31. PubMedCrossRef Koyama H, Ohno Y, Kono A, Takenaka D, Maniwa Y, Nishimura Y, et al. Quantitative and qualitative assessment of non-contrast-enhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects. Eur Radiol. 2008;18(10):2120–31. PubMedCrossRef
27.
Zurück zum Zitat Sugawara H, Watanabe H, Kunimatsu A, Abe O, Yatabe Y, Watanabe S, et al. Tumor size in patients with severe pulmonary emphysema might be underestimated on preoperative CT. Eur Radiol. 2022;32(1):163–73. PubMedCrossRef Sugawara H, Watanabe H, Kunimatsu A, Abe O, Yatabe Y, Watanabe S, et al. Tumor size in patients with severe pulmonary emphysema might be underestimated on preoperative CT. Eur Radiol. 2022;32(1):163–73. PubMedCrossRef
28.
Zurück zum Zitat Park CH, Kim TH, Lee S, Moon DH, Park HS. Correlation between maximal tumor diameter of fresh pathology specimens and computed tomography images in lung adenocarcinoma. PLoS ONE. 2019;14(1):1–13. CrossRef Park CH, Kim TH, Lee S, Moon DH, Park HS. Correlation between maximal tumor diameter of fresh pathology specimens and computed tomography images in lung adenocarcinoma. PLoS ONE. 2019;14(1):1–13. CrossRef
29.
Zurück zum Zitat Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, Vilstrup MH, Petersen H, Gerke O, et al. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules—a literature review. Eur J Nucl Med Mol Imaging. 2021;48:584–91. PubMedCrossRef Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, Vilstrup MH, Petersen H, Gerke O, et al. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules—a literature review. Eur J Nucl Med Mol Imaging. 2021;48:584–91. PubMedCrossRef
30.
Zurück zum Zitat Wiener JI, Chako AC, Merten CW, Gross S, Coffey EL, Stein HL. Breast and axillary tissue MR imaging: correlation of signal intensities and relaxation times with pathologic findings. Radiology. 1986;160(2):299–305. PubMedCrossRef Wiener JI, Chako AC, Merten CW, Gross S, Coffey EL, Stein HL. Breast and axillary tissue MR imaging: correlation of signal intensities and relaxation times with pathologic findings. Radiology. 1986;160(2):299–305. PubMedCrossRef
31.
Zurück zum Zitat Ohno Y, Hatabu H, Takenaka D, Higashino T, Watanabe H, Ohbayashi C, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology. 2004;231(3):872–9. PubMedCrossRef Ohno Y, Hatabu H, Takenaka D, Higashino T, Watanabe H, Ohbayashi C, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology. 2004;231(3):872–9. PubMedCrossRef
32.
Zurück zum Zitat Ohno Y, Koyama H, Yoshikawa T, Nishio M, Aoyama N, Onishi Y, et al. N stage disease in patients with non–small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology. 2011;261(2):605–15. PubMedCrossRef Ohno Y, Koyama H, Yoshikawa T, Nishio M, Aoyama N, Onishi Y, et al. N stage disease in patients with non–small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology. 2011;261(2):605–15. PubMedCrossRef
33.
Zurück zum Zitat Katsumata S, Aokage K, Ishii G, Nakasone S, Sakai T, Okada S, et al. Prognostic impact of the number of metastatic lymph nodes on the eighth edition of the TNM classification of NSCLC. J Thorac Oncol. 2019;14(8):1408–18. PubMedCrossRef Katsumata S, Aokage K, Ishii G, Nakasone S, Sakai T, Okada S, et al. Prognostic impact of the number of metastatic lymph nodes on the eighth edition of the TNM classification of NSCLC. J Thorac Oncol. 2019;14(8):1408–18. PubMedCrossRef
34.
Zurück zum Zitat Shang X, Liu J, Li Z, Lin J, Wang H. A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC. BMC Cancer. 2019;19(1):591. PubMedPubMedCentralCrossRef Shang X, Liu J, Li Z, Lin J, Wang H. A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC. BMC Cancer. 2019;19(1):591. PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Antoniou AJ, Marcus C, Tahari AK, Wahl RL, Subramaniam RM. Follow-up or surveillance 18F-FDG PET/CT and survival outcome in lung cancer patients. J Nucl Med. 2014;55(7):1062–8. PubMedCrossRef Antoniou AJ, Marcus C, Tahari AK, Wahl RL, Subramaniam RM. Follow-up or surveillance 18F-FDG PET/CT and survival outcome in lung cancer patients. J Nucl Med. 2014;55(7):1062–8. PubMedCrossRef
36.
Zurück zum Zitat Gregory DL, Hicks RJ, Hogg A, Binns DS, Shum PL, Milner A, et al. Effect of PET/CT on management of patients with non–small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53(7):1007–15. PubMedCrossRef Gregory DL, Hicks RJ, Hogg A, Binns DS, Shum PL, Milner A, et al. Effect of PET/CT on management of patients with non–small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53(7):1007–15. PubMedCrossRef
37.
Zurück zum Zitat Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918–24. PubMedCrossRef Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918–24. PubMedCrossRef
38.
Zurück zum Zitat Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small. Eur J Nucl Med Mol Imaging. 2006;33:263–9. PubMedCrossRef Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small. Eur J Nucl Med Mol Imaging. 2006;33:263–9. PubMedCrossRef
39.
Zurück zum Zitat Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected. J Nucl Med. 2002;43(1):39–45. PubMed Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected. J Nucl Med. 2002;43(1):39–45. PubMed
40.
Zurück zum Zitat Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23(6):1136–43. PubMedCrossRef Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23(6):1136–43. PubMedCrossRef
41.
Zurück zum Zitat Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell. J Thorac Cardiovasc Surg. 2005;130(1):151–9. PubMedCrossRef Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell. J Thorac Cardiovasc Surg. 2005;130(1):151–9. PubMedCrossRef
42.
Zurück zum Zitat Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI perform equally well in cancer: evidence from studies on more than 2300 patients. J Nucl Med. 2016;57(3):420–30. PubMedCrossRef Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI perform equally well in cancer: evidence from studies on more than 2300 patients. J Nucl Med. 2016;57(3):420–30. PubMedCrossRef
Metadaten
Titel
Consistency and prognostic value of preoperative staging and postoperative pathological staging using 18 F-FDG PET/MRI in patients with non-small cell lung cancer
verfasst von
Akiko Kajiyama
Kimiteru Ito
Hirokazu Watanabe
Sunao Mizumura
Shun-ichi Watanabe
Yasushi Yatabe
Tatsuya Gomi
Masahiko Kusumoto
Publikationsdatum
20.10.2022
Verlag
Springer Nature Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 12/2022
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01795-9

Weitere Artikel der Ausgabe 12/2022

Annals of Nuclear Medicine 12/2022 Zur Ausgabe